Listed

Northwest Biotherapeutics Inc: Form 10-Q for the period ended Jun 30, 2025

Filed with the SEC on Aug 14, 2025 and accepted by EDGAR at Aug 14, 2025, 17:00 ET.

Share

Management's discussion and analysis

As filed, 21,356 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and the notes to those statements included with this report. In addition to historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. The words “believe,” “expect,” “intend,” “anticipate,” and similar expressions are used to identify forward-looking statements, but some forward-looking statements are expressed differently. Many factors could affect our actual results, including those factors described under “Risk Factors” in our Form 10-K for the year ended December 31, 2024 and in Part II Item 1A of this report. These factors, among others, could cause results to differ materially from those presently anticipated by us. You should not rely upon on these forward-looking statements.

Overview

We are a biotechnology company focused on developing personalized immune therapies for cancer. We have developed a platform technology, DCVax®, which uses activated dendritic cells to mobilize a patient’s own immune system to attack their cancer.

Our lead product, DCVax®-L, is designed to treat solid tumor cancers in which the tumor can be surgically removed. We have completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM), published the results in the JAMA Oncology peer reviewed journal, and on December 20, 2023 we submitted a Marketing Authorization Application (MAA) for commercial approval in the U.K. We plan to conduct clinical trials of DCVax-L for other solid tumor cancers in the future, when resources permit. Our second product, DCVax®-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed, and included treatment of a diverse range of more than a dozen types of cancers. We plan to work on preparations for Phase II trials of DCVax-Direct as resources permit.

During the second quarter of 2025, the Company continued its progress on multiple fronts, including the following.

MAA Application. The Company and its teams of consultants continued to devote a large portion of their time to active engagement in the MAA process during the second quarter. As is typical, and as the Company has previously stated, the Company does not plan to make any interim announcements while its MAA is going through the regulatory process. The Company plans to announce the results when the regulatory review and decision-making is finished.

Comments on Potential New MHRA Policies. In the UK, the MHRA issued a draft Guideline of important potential new policies under which clinical trials would be allowed to use external controls instead of within-study placebo arms, especially for severe or rare diseases, and the MHRA called for public comments during the second quarter. The Company worked together with physician collaborators, patient groups, statisticians, academics and political representatives to help mobilize public comments.

Manufacturing in the Sawston, UK Facility. Building upon the design and engineering work in preceding months, the Company and Advent developed an improved design and configuration for the simplified Grade C lab. The Company and Advent also negotiated the construction arrangements and undertook preparations to enable construction to begin in the third quarter. The Company and Advent undertook strategic planning for consolidation of the operations in the London GMP facility and the Sawston GMP facility, to reduce overall costs and increase capacity in Sawston. The Company and Advent also undertook strategic planning for operations in the Sawston facility to increase the focus and resources on ramp-up of manufacturing relative to other operations such as product and process development (PD) now that years of intensive PD work for the MAA and the DCVax-Direct program have been completed by Advent.

Manufacturing in the US for In-licensed Technologies. The Company continued its progress on developing manufacturing capacity in the US for technologies that the Company has in-licensed. (The Sawston facility is handling the manufacturing of the Company’s DCVax-L and DCVax-Direct products for global use.) After extensive discussions in prior quarters with GMP facilities in several states, the Company selected two locations as the finalist candidates for development the US manufacturing capacity. The Company progressed with contract negotiations in both locations, and anticipates reaching an agreement in the near term. The Company also undertook personnel screening and selection processes for the specialized expertise required, and has secured certain initial key anchor personnel. The Company is in the process of negotiations with key equipment suppliers.

Potential Compassionate Use Programs in the US. The Company has had a compassionate use program in the UK for a number of years, and believes that those compassionate use cases have been helpful for the patients involved and have generated real world data that is quite useful. As previously reported, the Company is expanding its existing compassionate use program with additional clinics and doctors. The Company is also interested in undertaking a compassionate use program in the US when feasible. The Company has noted that well over a dozen US states have enacted expanded compassionate use legislation, including during this year to date, and that expanded access programs are also possible at the federal level. The Company is actively exploring the potential for expanded access/ compassionate use in the US.

DCVax-Direct Program. As previously reported, the Company has been developing INDs for the initial clinical trials with the Company’s new DCVax-Direct product. The manufacturing and product-related portions of the IND packages have been completed. The clinical portions are being further refined (including with respect to the selection of booster agent(s) as described below) in consultation with clinician/investigators. The Company is evaluating the potential to include certain technology elements in-licensed from Roswell Park, and is considering testing the treatments in ovarian cancer, building upon the positive results of the Company’s prior trial in late-stage ovarian cancer (for which there is a severe unmet need for new treatment options). The Company plans to proceed with the initial trial in the coming months.

Enhanced DCVax-Direct Products and Presentation. The Company made its first public presentation of some of the results of its ongoing internal research, testing certain immune booster agents that it has in-licensed, to identify the most useful booster agent(s) and combination(s) of agents for enhanced DCVax-Direct products. The Company presented these results at the New York Academy of Sciences in June. The Company is in the process of finalizing its decisions about which booster agent(s) and which enhanced DCVax-Direct products to test in the DCVax-Direct clinical trials pursuant to the INDs described above.

Litigation Progress. The Company’s lawsuit against certain market makers entered the long-awaited discovery phase during the second quarter. The Company is expanding its activities related to the case, and expects to further ramp up its activities in the coming months. The Company believes that the discovery process will potentially yield very important information, and the Company plans to continue pursuing the case vigorously. See Part II Item 1, Legal Proceedings, below.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect our reported amounts of assets, liabilities, revenues and expenses.

On an ongoing basis, we evaluate our estimates and judgments, including those related to derivative liabilities, accrued expenses and stock-based compensation. We based our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates.

Our critical accounting policies and significant estimates are detailed in our Annual Report on Form 10-K for the year ended December 31, 2024. Our critical accounting policies and significant estimates have not changed substantially from those previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2024.

Results of Operations

Operating costs:

Our operating costs and expenses consist primarily of research and development (R&D) expenses. R&D expenses include clinical trial expenses, and increased costs after completion of a Phase III trial, especially for the extensive preparations, and teams of expert consultants, required for an application for product approval.

In addition to clinical trial and post-trial costs, our operating costs may include ongoing work relating to our DCVax products, including R&D, product characterization, manufacturing process development, quality control process development, and related matters. Additional substantial costs relate to the development and expansion of manufacturing capacity.

Our operating costs also include the costs of preparations for the launch of new or expanded clinical trial programs, such as our anticipated trials of combination treatment regimens. The preparation costs include payments to regulatory consultants, lawyers, statisticians, sites and others, evaluation of potential investigators, the clinical trial sites and the CROs managing the trials and other service providers, and expenses related to institutional approvals, clinical trial agreements (business contracts with sites), training of medical and other site personnel, trial supplies and other.

Our operating costs also include legal and accounting costs in operating the Company.

The foregoing operating costs include the costs for Flaskworks’ ongoing operations and intellectual property filings, and the operations of our subsidiaries in the U.K., the Netherlands and Germany.

Research and development:

R&D expenses include costs for substantial external scientific personnel, technical and regulatory advisers, and others, costs of laboratory supplies used in our internal research and development projects, travel, regulatory compliance, and expenditures for preclinical and clinical trial operation and management when we are actively engaged in clinical trials.

Because we are a pre-revenue company, we do not allocate R&D costs on a project basis. We adopted this policy, in part, due to the unreasonable cost burden associated with accounting at such a level of detail and our limited number of financial and personnel resources.

General and administrative:

General and administrative expenses include personnel related salary and benefit expenses, cost of facilities, insurance, travel, legal services, property and equipment and amortization of stock options and warrants.

Three Months Ended June 30, 2025 and 2024

We recognized a net loss of $15.4 million and $17.9 million for the three months ended June 30, 2025 and 2024, respectively.

Research and Development Expense

For the three months ended June 30, 2025 and 2024, research and development expenses were $7.4 million and $8.3 million, respectively. The decrease in 2025 was primarily related to the decrease in stock-based compensation.

General and Administrative Expense

For the three months ended June 30, 2025 and 2024, general and administrative expenses were $7.5 million and $9.7 million, respectively. The decrease was mainly related to a reduction in legal costs due to certain reimbursements and reduction in scientific conference expenses.

Change in Fair Value of Derivatives

We recognized a non-cash gain of $0.7 million and $2.4 million for the three months ended June 30, 2025 and 2024, respectively. The non-cash revaluation gain was mainly due to the decrease of stock price and remaining life of certain liability classified warrants.

Change in Fair Value of Convertible Notes

We recognized a non-cash gain of $2.4 million and a non-cash loss of $0.2 million change in fair value of the convertible notes during the three months ended June 30, 2025 and 2024, respectively. The non-cash gain was resulted from the decrease of the Company’s stock price as of the date of remeasurement compared to prior period. The non-cash loss was resulted from the increase of the Company’s stock price as of the date of remeasurement compared to prior period.

Debt Extinguishment

We recognized approximately $4.5 million and $0.9 million debt extinguishment loss during the three months ended June 30, 2025 and 2024 from debt redemptions and debt amendments, respectively. The increase during the three months ended June 30, 2025 compared to last year was due to multiple amendments on the existing convertible notes which resulted a debt extinguishment loss of $2.8 million.

Loss from Issuance of Debt

During the three months ended June 30, 2025, we recognized an $0.8 million loss from the issuance of the June Yorkville Note, which we elected to account for under the FVO. The estimated fair value of the June Yorkville Note on the issuance date was approximately $3.8 million, which resulted in a loss of $0.8 million calculated at the difference between the principal amount and the fair value of the June Yorkville Note.

Interest Expense

During the three months ended June 30, 2025 and 2024, we recognized interest expense of $1.8 million and $1.7 million, respectively. The increase in interest expense in 2025 was mainly related to an increase of outstanding debt balance.

Foreign currency transaction gain (loss)

During the three months ended June 30, 2025 and 2024, we recognized foreign currency transaction gain of $3.6 million and a loss of $45,000, respectively. The gain was due to the strengthening of the British pound sterling relative to the U.S. dollar and vice versa for the loss.

Six Months Ended June 30, 2025 and 2024

We recognized a net loss of $34.7 million and $36.2 million for the six months ended June 30, 2025 and 2024, respectively.

Research and Development Expense

For the six months ended June 30, 2025 and 2024, research and development expenses were $15.8 million and $16.2 million, respectively. The decrease in 2025 was primarily related to the decrease in stock-based compensation and offset by an increased cost related to MAA application at the MHRA and the resumption of DCVax-Direct production.

General and Administrative Expense

For the six months ended June 30, 2025 and 2024, general and administrative expenses were $16.8 million and $17.8 million, respectively. The decrease was mainly related to a reduction in stock-based compensation and scientific conference expenses. an increase in legal expenses.

Change in Fair Value of Derivatives

We recognized a non-cash gain of $2.0 million and $2.5 million for the six months ended June 30, 2025 and 2024, respectively. The gain was primarily due to the decrease of our closing stock price as of June 30, 2025 and 2024 compared to December 31, 2024 and 2023.

Change in Fair Value of Convertible Notes

We recognized $6.1 million and $1.5 million non-cash gain from change in fair value of the convertible notes during the six months ended June 30, 2025 and 2024, respectively. The non-cash gain resulted from the decrease of the Company’s stock price.

Debt Extinguishment

We recognized approximately $11.8 million and $3.1 million debt extinguishment loss during the six months ended June 30, 2025 and 2024 from debt redemptions and debt amendments, respectively. The increase during the six months ended June 30, 2025 compared to last year was due to multiple amendments on the existing convertible notes which resulted a debt extinguishment loss of $8.5 million.

Loss from Issuance of Debt

During the six months ended June 30, 2025, we recognized an $0.8 million loss from the issuance of the June Yorkville Note, which we elected to account for under the FVO. The estimated fair value of the June Yorkville Note on the issuance date was approximately $3.8 million, which resulted in a loss of $0.8 million calculated at the difference between the principal amount and the fair value of the June Yorkville Note.

Interest Expense

During the six months ended June 30, 2025 and 2024, we recognized interest expense of $3.4 million and $3.2 million, respectively. The increase in interest expense in 2025 was mainly related to an increase of outstanding debt balance.

Foreign currency transaction gain (loss)

During the six months ended June 30, 2025 and 2024, we recognized foreign currency transaction gain of $5.5 million and a loss of $0.7 million, respectively. The gain was due to the strengthening of the British pound sterling relative to the U.S. dollar and vice versa for the loss.

Liquidity and Capital Resources

We have experienced recurring losses from operations since inception. We have not yet established an ongoing source of material revenues and must cover our operating expenses through debt and equity financings to allow us to continue as a going concern. Our ability to continue as a going concern depends on the ability to obtain adequate capital to fund operating losses until we generate adequate cash flows from operations to fund our operating costs and obligations. If we are unable to obtain adequate capital, we could be forced to cease operations.

We depend upon our ability, and will continue to attempt, to secure equity and/or debt financing. We cannot be certain that additional funding will be available on acceptable terms, or at all. Our management determined that there was substantial doubt about our ability to continue as a going concern for at least one year after the annual consolidated financial statements were issued, and management’s concerns about our ability to continue as a going concern within the year following this report persist.

Cash Flow

Operating Activities

During the six months ended June 30, 2025 and 2024, net cash outflows from operations were approximately $16.1 million and $28.6 million, respectively. The decrease in cash used in operating activities was primarily attributable to lower payments for clinical trial related expenditures, insurance costs and certain consulting expenditures.

Investing Activities

We spent approximately $0.4 million and $0.8 million in cash for the purchase of additional equipment and our build-out in Sawston, UK during the six months ended June 30, 2025 and 2024, respectively.

Financing Activities

We received approximately $12.4 million and $2.9 million cash from issuance of 56.1 million and 8.1 million shares of common stock during the six months ended June 30, 2025 and 2024, respectively.

We received approximately $7.9 million of cash from issuance of 0.7 million shares of Series C convertible preferred stock during the six months ended June 30, 2024.

We received approximately $5.5 million and $7.1 million of cash from issuance of convertible notes to individual lenders during the six months ended June 30, 2025 and 2024, respectively.

We received approximately $7.0 million of cash from the issuance of a loan from a commercial lender during the six months ended June 30, 2025. We received approximately $10.0 million of cash from the issuance of a loan from a commercial lender during the six months ended June 30, 2024.

We received approximately $23,000 and $1.5 million of cash from the exercise of warrants during the six months ended June 30, 2025 and 2024, respectively.

We received $50,000 from issuance of non-dilutive funding agreements during the six months ended June 30, 2024.

We made aggregate debt payments of $0.8 million and $0.2 million during the six months ended June 30, 2025 and 2024, respectively.

Other factors affecting our ongoing funding requirements include the number of staff we employ, the number of sites, number of patients and amount of activity in our clinical trial programs, the costs of further product and process development work relating to our DCVax products, the costs of preparations for Phase II trials, the costs of expansion of manufacturing, and unanticipated developments. The extent of resources available to us will determine which programs can move forward and at what pace.

Off-Balance Sheet Arrangements

Since our inception, we have not engaged in any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

Market risk

As filed, 2,778 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Market risk represents the risk of loss that may result from the change in value of financial instruments due to fluctuations in its market price. Market risk is inherent in all financial instruments. Market risk may be exacerbated in times of trading illiquidity when market participants refrain from transacting in normal quantities and/or at normal bid-offer spreads. Our exposure to market risk is directly related to derivatives, debt and equity linked instruments related to our financing activities.

Our assets and liabilities are overwhelmingly denominated in U.S. dollars. We do not use foreign currency contracts or other derivative instruments to manage changes in currency rates. We do not now, nor do we plan to, use derivative financial instruments for speculative or trading purposes. However, these circumstances might change.

The primary quantifiable market risk associated with our financial instruments is sensitivity to changes in interest rates. Interest rate risk represents the potential loss from adverse changes in market interest rates. We use an interest rate sensitivity simulation to assess our interest rate risk exposure. For purposes of presenting the possible earnings effect of a hypothetical, adverse change in interest rates over the 12-month period from our reporting date, we assume that all interest rate sensitive financial instruments will be impacted by a hypothetical, immediate 100 basis point increase in interest rates as of the beginning of the period. The sensitivity is based upon the hypothetical assumption that all relevant types of interest rates that affect our results would increase instantaneously, simultaneously and to the same degree. We do not believe that our cash and equivalents have significant risk of default or illiquidity.

The sensitivity analyses of the interest rate sensitive financial instruments are hypothetical and should be used with caution. Changes in fair value based on a 1% or 2% variation in an estimate generally cannot be extrapolated because the relationship of the change in the estimate to the change in fair value may not be linear. Also, the effect of a variation in a particular estimate on the fair value of financial instruments is calculated independent of changes in any other estimate; in practice, changes in one factor may result in changes in another factor, which might magnify or counteract the sensitivities. In addition, the sensitivity analyses do not consider any action that we may take to mitigate the impact of any adverse changes in the key estimates.

Based on our analysis, as of June 30, 2025, the effect of a 100+/- basis point change in interest rates on the value of our financial instruments and the resultant effect on our net loss are considered immaterial.

Controls and procedures

As filed, 1,237 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation as of June 30, 2025, of the design and operation of our disclosure controls and procedures, as such terms are defined in Exchange Act Rules 13a-15(e) and 15d-15(e). Based on this evaluation, management concluded that, as of such date, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

No change in internal control over financial reporting occurred during the most recent quarter with respect to our operations, which materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2025-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2025-04-01 to 2025-06-30$131.0kus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue6 months2025-01-01 to 2025-06-30$506.0kus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development3 months2025-04-01 to 2025-06-30$7.4mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2025-01-01 to 2025-06-30$15.8mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2025-04-01 to 2025-06-30−$14.8mus-gaap:OperatingIncomeLoss
Operating income6 months2025-01-01 to 2025-06-30−$32.1mus-gaap:OperatingIncomeLoss
Interest expense3 months2025-04-01 to 2025-06-30$1.8mus-gaap:InterestExpenseNonoperating
Interest expense6 months2025-01-01 to 2025-06-30$3.4mus-gaap:InterestExpenseNonoperating
Net income3 months2025-04-01 to 2025-06-30−$15.4mus-gaap:NetIncomeLoss
Net income6 months2025-01-01 to 2025-06-30−$34.7mus-gaap:NetIncomeLoss
Diluted EPS3 months2025-04-01 to 2025-06-30−$0.01us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2025-01-01 to 2025-06-30−$0.03us-gaap:EarningsPerShareDiluted
Basic EPS3 months2025-04-01 to 2025-06-30−$0.01us-gaap:EarningsPerShareBasic
Basic EPS6 months2025-01-01 to 2025-06-30−$0.03us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2025-04-01 to 2025-06-301,438,198 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2025-01-01 to 2025-06-301,399,064 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2025-01-01 to 2025-06-30−$16.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2025-01-01 to 2025-06-30$397.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2025-06-30$4.3mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2025-06-30$6.2mus-gaap:AssetsCurrent
Total assetsAt period end2025-06-30$29.5mus-gaap:Assets
Current liabilitiesAt period end2025-06-30$83.9mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2025-06-30$116.2mus-gaap:Liabilities
Long-term debtAt period end2025-06-30$64.7mus-gaap:LongTermDebt
Shareholders' equityAt period end2025-06-30−$100.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001410578-25-001825. Last ingested by Listed: Nov 14, 2026, 21:35 ET. Listed shows no prices and gives no investment advice.